{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T22:12:10Z","timestamp":1767651130810},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2015,10,6]],"date-time":"2015-10-06T00:00:00Z","timestamp":1444089600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1007\/s10620-015-3893-4","type":"journal-article","created":{"date-parts":[[2015,10,6]],"date-time":"2015-10-06T09:06:16Z","timestamp":1444122376000},"page":"589-596","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["The Tolerability and Efficacy of Rapid Infliximab Infusions in Patients with Inflammatory Bowel Disease"],"prefix":"10.1007","volume":"61","author":[{"given":"Taha","family":"Qazi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bhavesh","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed","family":"El-Dib","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francis A.","family":"Farraye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,10,6]]},"reference":[{"key":"3893_CR1","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1056\/NEJMoa050516","volume":"353","author":"P Rutgeerts","year":"2005","unstructured":"Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353:2462\u20132476.","journal-title":"N Engl J Med"},{"key":"3893_CR2","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1056\/NEJM199710093371502","volume":"337","author":"SR Targan","year":"1997","unstructured":"Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn\u2019s disease. Crohn\u2019s Disease cA2 Study Group. N Engl J Med. 1997;337:1029\u20131035.","journal-title":"N Engl J Med"},{"key":"3893_CR3","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","volume":"359","author":"SB Hanauer","year":"2002","unstructured":"Hanauer SB, Feagan BG, Lichtenstein GR, et al. ACCENT I Study Group. Maintenance infliximab for Crohn\u2019s disease: the ACCENT I randomised trial. Lancet. 2002;359:1541\u20131549.","journal-title":"Lancet"},{"key":"3893_CR4","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/S1542-3565(04)00414-8","volume":"2","author":"BE Sands","year":"2004","unstructured":"Sands BE, Blank MA, Patel K, van Deventer SJ. Long-term treatment of rectovaginal fistulas in Crohn\u2019s disease: response to infliximab in the ACCENT II Study. Clin Gastroenterol Hepatol. 2004;2:912\u2013920.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"3893_CR5","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1056\/NEJMoa030815","volume":"350","author":"BE Sands","year":"2004","unstructured":"Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn\u2019s disease. N Engl J Med. 2004;350:876\u2013885.","journal-title":"N Engl J Med"},{"key":"3893_CR6","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1056\/NEJM199905063401804","volume":"340","author":"DH Present","year":"1999","unstructured":"Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn\u2019s disease. N Engl J Med. 1999;340:1398\u20131405.","journal-title":"N Engl J Med"},{"key":"3893_CR7","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/ajg.2009.727","volume":"105","author":"A Kornbluth","year":"2010","unstructured":"Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2010;105:501\u2013523.","journal-title":"Am J Gastroenterol"},{"key":"3893_CR8","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/ajg.2008.168","volume":"104","author":"GR Lichtenstein","year":"2009","unstructured":"Lichtenstein GR, Hanauer SB, Sandborn WJ. Management of Crohn\u2019s disease in adults. Am J Gastroenterol. 2009;104:465\u2013483.","journal-title":"Am J Gastroenterol"},{"key":"3893_CR9","first-page":"A697","volume":"130","author":"A Gramlick","year":"2006","unstructured":"Gramlick A, Fossati G, Nesbitt AM. Neutralization of soluble and membrane tumor necrosis factor-alpha (TNF- alpha) by infliximab, adalimumab, or certolizumab pegol using P55 or P75 TNF-alpha receptor specific bioassays. Gastroenterology. 2006;130:A697.","journal-title":"Gastroenterology"},{"key":"3893_CR10","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1053\/j.gastro.2004.01.036","volume":"26","author":"H Mitoma","year":"2004","unstructured":"Mitoma H, Horiuchi T, Tsukamoto H. Binding activities of infliximab and etanercept to transmembrane tumor necrosis factor-alpha. Gastroenterology. 2004;26:934\u2013935.","journal-title":"Gastroenterology"},{"key":"3893_CR11","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1053\/gast.2001.28702","volume":"121","author":"A Lugering","year":"2001","unstructured":"Lugering A, Schmidt M, Lugering N, Pauels HG, Domschke W, Kucharzik T. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn\u2019s disease by using a caspase-dependent pathway. Gastroenterology. 2001;121:1145\u20131457.","journal-title":"Gastroenterology"},{"key":"3893_CR12","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1111\/j.1572-0241.2003.07457.x","volume":"98","author":"A Cheifetz","year":"2003","unstructured":"Cheifetz A, Smedley M, Martin S, et al. The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol. 2003;98:1315\u20131324.","journal-title":"Am J Gastroenterol"},{"key":"3893_CR13","doi-asserted-by":"crossref","first-page":"29C","DOI":"10.1155\/2000\/698523","volume":"14","author":"TF Schaible","year":"2000","unstructured":"Schaible TF. Long term safety of infliximab. Can J Gastroenterol. 2000;14:29C\u201332C.","journal-title":"Can J Gastroenterol"},{"key":"3893_CR14","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1136\/ard.2003.017590","volume":"64","author":"RF Vollenhoven van","year":"2005","unstructured":"van Vollenhoven RF, Gullstrom E, Klareskog L. Feasibility of 1\u00a0h infliximab infusions. Ann Rheum Dis. 2005;64:654.","journal-title":"Ann Rheum Dis"},{"key":"3893_CR15","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1093\/rheumatology\/kei247","volume":"45","author":"MH Buch","year":"2006","unstructured":"Buch MH, Bryer D, Lindsay S, et al. Shortening infusion times for infliximab administration. Rheumatology. 2006;45:485\u2013486.","journal-title":"Rheumatology"},{"key":"3893_CR16","first-page":"A629","volume":"126","author":"B Salzberg","year":"2004","unstructured":"Salzberg B, Kendall K. Successful 1 h infusions of infliximab for Crohn\u2019s disease patients in an outpatient office setting. Gastroenterology. 2004;126:A629.","journal-title":"Gastroenterology"},{"key":"3893_CR17","doi-asserted-by":"crossref","first-page":"A402","DOI":"10.1016\/S0016-5085(08)61877-6","volume":"134","author":"R Befrits","year":"2008","unstructured":"Befrits R, Malmstr\u00f6m L, Forsell A, et al. One hour infliximab infusions can replace 2\u00a0h infusion in maintenance treatment of Crohn\u2019s disease without shortcomings, in patients treated for up to 3\u00a0years. Gastroenterology. 2008;134:A402.","journal-title":"Gastroenterology"},{"key":"3893_CR18","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1002\/ibd.21279","volume":"16","author":"S Bhat","year":"2010","unstructured":"Bhat S, Sharma D, et al. Are accelerated infliximab infusions safe in patients with inflammatory bowel disease? Inflamm Bowel Dis. 2010;16:1922\u20131925.","journal-title":"Inflamm Bowel Dis"},{"key":"3893_CR19","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/MEG.0b013e3283081afe","volume":"21","author":"DF Clare","year":"2009","unstructured":"Clare DF, Alexander FC, Mike S, et al. Accelerated infliximab infusions are safe and well tolerated in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2009;21:71\u201375.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"3893_CR20","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.crohns.2009.12.012","volume":"4","author":"G Assche Van","year":"2010","unstructured":"Van Assche G, Vermeire S, Noman M, et al. Infliximab administered with shortened infusion times in a specialized IBD infusion unit: a prospective cohort study. J Crohns Colitis. 2010;4:329\u2013333.","journal-title":"J Crohns Colitis"},{"key":"3893_CR21","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.crohns.2012.03.007","volume":"7","author":"A Barbouri","year":"2013","unstructured":"Barbouri A, Buisson A, Bigard MA, et al. Tolerability of 1\u00a0h 10\u00a0mg\/kg infliximab infusions in patients with inflammatory bowel disease. J Crohns Colitis. 2013;7:129\u2013133.","journal-title":"J Crohns Colitis"},{"key":"3893_CR22","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1038\/ajg.2011.61","volume":"106","author":"C Breynaert","year":"2011","unstructured":"Breynaert C, Ferrante M, Fidder H, et al. Tolerability of shortened infliximab infusion times in patients with inflammatory bowel diseases: a single-center cohort study. Am J Gastroenterology. 2011;106:778\u2013785.","journal-title":"Am J Gastroenterology"},{"key":"3893_CR23","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/apt.12389","volume":"38","author":"HC Neef","year":"2013","unstructured":"Neef HC, Riebschleger MP, Adler J. Meta-analysis: rapid infliximab infusions are safe. Aliment Pharmacol Ther. 2013;38:365\u2013376.","journal-title":"Aliment Pharmacol Ther"},{"key":"3893_CR24","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/ibd.21697","volume":"18","author":"W Reinisch","year":"2012","unstructured":"Reinisch W, Sandborn W, Rutgeerts P, et al. Long-term infliximab maintenance therapy for ulcerative colitis: the ACT-1 and -2 extension studies. Inflamm Bowel Dis. 2012;18:201\u2013211.","journal-title":"Inflamm Bowel Dis"},{"key":"3893_CR25","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1111\/j.1365-2036.2011.04986.x","volume":"35","author":"E Rostholder","year":"2012","unstructured":"Rostholder E, Ahmed A, Cheifetz S, et al. Outcomes after escalation of infliximab therapy in ambulatory patients with moderately active ulcerative colitis. Aliment Pharmacol Ther. 2012;35:562\u2013567.","journal-title":"Aliment Pharmacol Ther"},{"key":"3893_CR26","doi-asserted-by":"crossref","first-page":"S355","DOI":"10.1016\/S0016-5085(12)61337-7","volume":"142","author":"C Taxonera","year":"2012","unstructured":"Taxonera C, Barreiro-de Acosta M, Calvo M, et al. Short- and long-term outcomes of infliximab dose intensification in patients with ulcerative colitis. Gastroenterology. 2012;142:S355.","journal-title":"Gastroenterology"},{"key":"3893_CR27","doi-asserted-by":"crossref","first-page":"S440","DOI":"10.14309\/00000434-200910003-01189","volume":"104","author":"M Lazarev","year":"2009","unstructured":"Lazarev M, Ullman T, Mayer L, et al. The need for infliximab dose escalation in ulcerative colitis [abstract]. Am J Gastroenterol. 2009;104:S440.","journal-title":"Am J Gastroenterol"},{"key":"3893_CR28","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1002\/ibd.20177","volume":"13","author":"M Regueiro","year":"2007","unstructured":"Regueiro M, Siemanowski B, Kip K, et al. Infliximab dose intensification in Crohn\u2019s disease. Inflamm Bowel Dis. 2007;13:1093\u20131099.","journal-title":"Inflamm Bowel Dis"},{"key":"3893_CR29","doi-asserted-by":"crossref","first-page":"A631","DOI":"10.1053\/j.gastro.2003.12.034","volume":"126","author":"CE Shih","year":"2004","unstructured":"Shih CE, Bayless TM, Harris ML. Maintenance of long term response to infliximab over 1\u20135\u00a0years in Crohn\u2019s Disease including shortening dosing intervals or increasing dosage. Gastroenterology. 2004;126:A631.","journal-title":"Gastroenterology"},{"key":"3893_CR30","first-page":"A587","volume":"128","author":"D Thameem","year":"2005","unstructured":"Thameem D, Kugathasan S, Hatoum OA, et al. Acceleration of infliximab maintenance therapy in Crohn\u2019s Disease. Gastroenterology. 2005;128:A587.","journal-title":"Gastroenterology"},{"key":"3893_CR31","doi-asserted-by":"crossref","first-page":"S470","DOI":"10.1111\/j.1572-0241.2006.00001_9.x","volume":"101","author":"S Corman","year":"2006","unstructured":"Corman S, Issa M, Beaulieu DB, et al. Escalation of infliximab maintenance therapy in Crohn\u2019s Disease. Am J Gastroenterol. 2006;101:S470.","journal-title":"Am J Gastroenterol"},{"key":"3893_CR32","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1136\/gutjnl-2013-305259","volume":"63","author":"B Ungar","year":"2014","unstructured":"Ungar B, Chowers Y, Yavzori M, et al. The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab. Gut. 2014;63:1258\u20131264.","journal-title":"Gut"},{"key":"3893_CR33","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.1007\/s10620-012-2289-y","volume":"57","author":"C Gunnarsson","year":"2012","unstructured":"Gunnarsson C, Chen J, Rizzo JA, et al. Direct health care insurer and out-of-pocket expenditures of inflammatory bowel disease: evidence from a national survey. Dig Dis Sci. 2012;57:3080\u20133091.","journal-title":"Dig Dis Sci"},{"key":"3893_CR34","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1002\/ibd.21488","volume":"17","author":"KT Park","year":"2011","unstructured":"Park KT, Bass D. Inflammatory bowel disease-attributable costs and cost-effective strategies in the United States: a review. Inflamm Bowel Dis. 2011;17:1603\u20131609.","journal-title":"Inflamm Bowel Dis"},{"key":"3893_CR35","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa020888","volume":"348","author":"F Baert","year":"2003","unstructured":"Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long -term efficacy of infliximab in Crohn\u2019s disease. N Engl J Med. 2003;348:601\u2013608.","journal-title":"N Engl J Med"},{"key":"3893_CR36","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/ajg.2012.363","volume":"108","author":"KS Nanda","year":"2013","unstructured":"Nanda KS, Cheifetz AS, Moss AC. Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis. Am J Gastroenterol. 2013;108:40\u201347.","journal-title":"Am J Gastroenterol"},{"key":"3893_CR37","unstructured":"CMS-1601-FC Medicare and Medicaid Programs: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems and Quality Reporting Programs; Final Rule with Comment Period, Addendum B; displayed November 27, 2013, at: http:\/\/www.ofr.gov\/OFRUpload\/OFRData\/2013-28737_PI.pdf"},{"key":"3893_CR38","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1053\/j.gastro.2013.10.047","volume":"145","author":"JP Terdiman","year":"2013","unstructured":"Terdiman JP, Gruss CB, Heidelbaugh JJ, et al. American gastroenterological association institute guideline on the use of thiopurines, methotrexate, and anti-TNF-\u03b1 biologic drugs for the induction and maintenance of remission in inflammatory Crohn\u2019s disease. Gastroenterology. 2013;145:1459\u20131463.","journal-title":"Gastroenterology"},{"key":"3893_CR39","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.crohns.2012.09.002","volume":"6","author":"A Dignass","year":"2012","unstructured":"Dignass A, Linday JO, Sturm A, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 2: current management. J Crohn\u2019s Colitis. 2012;6:991\u20131030.","journal-title":"J Crohn\u2019s Colitis"},{"key":"3893_CR40","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.crohns.2009.12.002","volume":"4","author":"A Dignass","year":"2010","unstructured":"Dignass A, Van Assche G, Lindsay J, et al. The second European evidence-based consensus on the diagnosis and management of Crohn\u2019s disease: current Management. J Crohn\u2019s Colitis. 2010;4:28\u201362.","journal-title":"J Crohn\u2019s Colitis"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-015-3893-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10620-015-3893-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-015-3893-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,9]],"date-time":"2020-09-09T07:00:30Z","timestamp":1599634830000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10620-015-3893-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10,6]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["3893"],"URL":"https:\/\/doi.org\/10.1007\/s10620-015-3893-4","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10,6]]}}}